2022
Lifestyle and personal factors associated with having macroscopic residual disease after ovarian cancer primary cytoreductive surgery
Phung M, Webb P, DeFazio A, Fereday S, Lee A, Bowtell D, Fasching P, Goode E, Goodman M, Karlan B, Lester J, Matsuo K, Modugno F, Brenton J, Van Gorp T, Pharoah P, Schildkraut J, McLean K, Meza R, Mukherjee B, Richardson J, Grout B, Chase A, Deurloo C, Terry K, Hanley G, Pike M, Berchuck A, Ramus S, Pearce C, Consortium O. Lifestyle and personal factors associated with having macroscopic residual disease after ovarian cancer primary cytoreductive surgery. Gynecologic Oncology 2022, 168: 68-75. PMID: 36401943, PMCID: PMC10398872, DOI: 10.1016/j.ygyno.2022.10.018.Peer-Reviewed Original ResearchConceptsHigh-grade serous ovarian cancerEstrogen-only therapyPrimary cytoreductive surgeryMacroscopic residual diseaseResidual diseaseParous womenFamily history of ovarian cancerOvarian Cancer Association ConsortiumMenopausal hormone therapy useHistory of ovarian cancerFirst-degree family historyCytoreductive surgeryOvarian cancer riskOvarian cancerAdvanced stage high-grade serous ovarian cancerPresence of macroscopic residual diseaseHormone therapy useHigh-grade serous ovarian cancer patientsDepot medroxyprogesterone acetate useBody mass indexLogistic regression modelsOral contraceptive useIncomplete pregnanciesSerous ovarian cancerFactors influencing survivalHigh pre-diagnosis inflammation-related risk score associated with decreased ovarian cancer survival
Brieger KK, Phung MT, Mukherjee B, Bakulski KM, Anton-Culver H, Bandera EV, Bowtell DDL, Cramer DW, DeFazio A, Doherty JA, Fereday S, Fortner RT, Gentry-Maharaj A, Goode EL, Goodman MT, Harris HR, Matsuo K, Menon U, Modugno F, Moysich KB, Qin B, Ramus SJ, Risch HA, Rossing MA, Schildkraut JM, Trabert B, Vierkant RA, Winham SJ, Wentzensen N, Wu AH, Ziogas A, Khoja L, Cho KR, McLean K, Richardson J, Grout B, Chase A, Deurloo CM, Odunsi K, Nelson BH, Brenton JD, Terry KL, Pharaoh P, Berchuck A, Hanley GE, Webb PM, Pike MC, Pearce CL. High pre-diagnosis inflammation-related risk score associated with decreased ovarian cancer survival. Cancer Epidemiology Biomarkers & Prevention 2022, 31: cebp.epi-21-0977-a.2021. PMID: 34789471, PMCID: PMC9281656, DOI: 10.1158/1055-9965.epi-21-0977.Peer-Reviewed Original ResearchConceptsOvarian cancer survivalCox proportional hazards modelProportional hazards modelCancer survivalOvarian cancerRisk scoreHazards modelNonsteroidal anti-inflammatory drug useAnti-inflammatory drug useMenopausal hormone therapy useEnvironmental tobacco smoke exposureInvasive epithelial ovarian cancerHormone therapy usePelvic inflammatory diseaseInflammation-related factorsPolycystic ovarian syndromeTobacco smoke exposureBody mass indexRisk of deathEpithelial ovarian cancerOvarian Cancer Association ConsortiumOvarian cancer diagnosisHigh death rateAspirin useOvarian syndrome
2021
Endometriosis and menopausal hormone therapy impact the hysterectomy-ovarian cancer association
Khoja L, Weber RP, Group T, Webb PM, Jordan SJ, Muthukumar A, Chang-Claude J, Fortner RT, Jensen A, Kjaer SK, Risch H, Doherty JA, Harris HR, Goodman MT, Modugno F, Moysich K, Berchuck A, Schildkraut JM, Cramer D, Terry KL, Anton-Culver H, Ziogas A, Phung MT, Hanley GE, Wu AH, Mukherjee B, McLean K, Cho K, Pike MC, Pearce CL, Lee AW. Endometriosis and menopausal hormone therapy impact the hysterectomy-ovarian cancer association. Gynecologic Oncology 2021, 164: 195-201. PMID: 34776242, PMCID: PMC9444325, DOI: 10.1016/j.ygyno.2021.10.088.Peer-Reviewed Original ResearchConceptsHistory of endometriosisOvarian cancer riskEPT useOvarian Cancer Association ConsortiumOvarian cancerInverse associationOdds ratioCancer riskCancer associationInvasive epithelial ovarian cancerHormone therapy useMenopausal hormone therapyEpithelial ovarian cancerCase-control studyConfidence intervalsSlight inverse associationWarrants further investigationHormone therapyTherapy usePooled analysisEndometriosisHysterectomyCancerTherapySelf-reported data
2020
Menopausal hormone therapy prior to the diagnosis of ovarian cancer is associated with improved survival
Brieger KK, Peterson S, Lee AW, Mukherjee B, Bakulski KM, Alimujiang A, Anton-Culver H, Anglesio MS, Bandera EV, Berchuck A, Bowtell DDL, Chenevix-Trench G, Cho KR, Cramer DW, DeFazio A, Doherty JA, Fortner RT, Garsed DW, Gayther SA, Gentry-Maharaj A, Goode EL, Goodman MT, Harris HR, Høgdall E, Huntsman DG, Shen H, Jensen A, Johnatty SE, Jordan SJ, Kjaer SK, Kupryjanczyk J, Lambrechts D, McLean K, Menon U, Modugno F, Moysich K, Ness R, Ramus SJ, Richardson J, Risch H, Rossing MA, Trabert B, Wentzensen N, Ziogas A, Terry KL, Wu AH, Hanley GE, Pharoah P, Webb PM, Pike MC, Pearce CL, Consortium F. Menopausal hormone therapy prior to the diagnosis of ovarian cancer is associated with improved survival. Gynecologic Oncology 2020, 158: 702-709. PMID: 32641237, PMCID: PMC7487048, DOI: 10.1016/j.ygyno.2020.06.481.Peer-Reviewed Original ResearchConceptsMenopausal hormone therapyOvarian cancer survivalMHT useResidual diseaseHormone therapyCancer survivalOvarian cancerHigh-grade serous carcinomaMacroscopic residual diseaseHormone therapy useFavorable prognostic factorPost-menopausal womenOvarian Cancer Association ConsortiumProportional hazards modelRecency of useImproved survivalPrognostic factorsTherapy useSerous carcinomaOvarian carcinomaHazards modelSmall studyAdvanced stageLarger studyLogistic regressionEstrogen Plus Progestin Hormone Therapy and Ovarian Cancer: A Complicated Relationship Explored.
Lee A, Wu A, Wiensch A, Mukherjee B, Terry K, Harris H, Carney M, Jensen A, Cramer D, Berchuck A, Doherty J, Modugno F, Goodman M, Alimujiang A, Rossing M, Cushing-Haugen K, Bandera E, Thompson P, Kjaer S, Hogdall E, Webb P, Huntsman D, Moysich K, Lurie G, Ness R, Stram D, Roman L, Pike M, Pearce C. Estrogen Plus Progestin Hormone Therapy and Ovarian Cancer: A Complicated Relationship Explored. Epidemiology 2020, 31: 402-408. PMID: 32028322, PMCID: PMC7584395, DOI: 10.1097/ede.0000000000001175.Peer-Reviewed Original ResearchConceptsRisk of ovarian cancerEstrogen-progestin combined therapyEstrogen-alone therapyAssociated with increased riskOvarian cancerCombination therapyRisk of ovarian cancer overallAssociated with increased risk of ovarian cancerOvarian cancer risk factorsPopulation-based case-control studyOvarian Cancer Association ConsortiumMenopausal hormone therapy useIncreased risk of endometrial cancerOvarian cancer overallRisk of endometrial cancerCancer risk factorsHistotypes of ovarian cancerRisk factorsProgestin hormone therapyMucinous ovarian cancerOvarian cancer casesIn-person interviewsHormone therapy useOvarian cancer histotypesCase-control study